Xilio Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary

Xilio Therapeutics

12/08/2026 14:32

Xilio Therapeutics Inc XLO.OQ reported a quarterly adjusted loss of 33 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of $-2.24.  The lone analyst forecast for the quarter was for a loss of 59 cents per share. 
Revenue rose 131.2% to $18.69 million from a year ago; analysts expected $12.72 million. 
Xilio Therapeutics Inc's reported EPS for the quarter was a loss of 33 cents​.
The company reported a quarterly loss of $6.37 million.
Xilio Therapeutics Inc shares had fallen by 4.2% this quarter and gained 2.4% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts was unchanged in the last three months.​ 
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 1 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is  "buy."
Wall Street's median 12-month price target for Xilio Therapeutics Inc is $20.00, about 54.1% above its last closing price of $9.18
This summary was machine generated from LSEG data August 12 at 01:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-0.59
-0.33
Beat
Mar. 31 2026 
-0.66
-0.58
Beat
Dec. 31 2025 
-1.68
0.81
Beat
Sep. 30 2025 
-0.42
-0.08
Beat